Monthly Archives: May 2019

GrowGeneration Corp (OTCMKTS:GRWG) Acquires The Assets GreenLife Garden Supply’s Assets And Adds Revenues Of $7 Million

GrowGeneration Corp (OTCMKTS:GRWG) Acquires The Assets GreenLife Garden Supply’s Assets And Adds Revenues Of $7 Million

GrowGeneration Corp (OTCMKTS:GRWG) has taken over the assets of England based GreenLife Garden Supply. The recent takeover adds revenues of $7 million to the company. Following the takeover, GrowGen is well positioned to service customers in New Jersey and New York. The company is expected to benefit a lot as these states are actively considering the legalization of adult use marijuana.

GreenLife is one of the highest and biggest volume of hydroponic chains in England. Sean Reardon, the founder of GreenLife, will continue in the role of the executive (sales and business development) for GrowGen.

The takeover allows GrowGen gets access to 5 warehouse and retail locations and service more commercial cultivators in New England. It already serves home and commercial growers from the existing 21 locations.

Marijuana market

The market for marijuana in Maine is expected to reach $325 million by next year. Maine is on track to open the market for adult use marijuana by the end of 2019. The state is framing rules for adult use marijuana.

Massachusetts has a hundred recreational business licenses. The sales of recreational marijuana are estimated at $100 million.

The annual revenues of recreational marijuana are expected to reach $300 million. Nearly 1.3 million people in New York could get access to the legal market, and the state could generate tax revenues of up to $677.7 million.

The annual sales of recreational marijuana in New Jersey are expected to reach up to $1.5 billion by the year 2023, according to Marijuana Business Daily. The state has 9 million people and expects 100 million visitors every year and creates a robust market for legal marijuana.

Growth prospects

GrowGen, which is one of the fastest and largest growing chains of hydroponic garden centers, has achieved consistent growth through the aggressive inauguration of new locations and acquisitions.

The company also operates the business through 5 wholly owned subsidiaries. GrowGeneration Canada Corp., the first subsidiary of GrowGen, expands business operations in Canada.

GrowGeneration Management Corp is its second subsidiary and has a team of ten commercial experts.

GrowGen has improved the performance in Q1 2019.  It has recorded 200% increase year on year and a 50% increase when compared to the previous quarter. Heavy Gardens, the newly purchased e-commerce store, has contributed to the revenues of $700,000.

Published at Thu, 30 May 2019 07:23:52 +0000

Marijuana Stocks Thursday Morning Update – May 30, 2019

Marijuana Stocks Thursday Morning Update – May 30, 2019

marijuana stocks to watch summer

We’ve got two days left this month so let’s finish strong. The markets are more upbeat this morning which could open the door for early momentum. With that, we’ve got breaking news and articles to get you ready to make it a #ProfitableThursday

Marijuana Stocks Remain Top Notch Amongst Investors

The marijuana stock market has remained quite interesting for some time now. With so many different factors aiding in what happens throughout the market, it seems as though at times it can be difficult to keep up with where the industry is headed. So many companies in the industry have been competing for space at the top, but only a few have shown that they have what it takes to make it there…


Marijuana Stocks Continue to Show Bullish Trends Into the Beginning of Summer

The marijuana stock market has remained quite bullish for some time now. In the past year alone, there have been some dramatic shifts to the industry, allowing companies to continue moving toward their high future goals. With so much going on, it can at times be confusing to keep up with the ever-shifting marketplace. There are, however, some companies that have continued to illustrate just how important they are to the functionality of the space, as well as how much potential they have for investors. All in all, there are a lot of options when it comes to investing in marijuana, but the most important thing to note is to always do the proper research.


Nabis Holdings (CSE: NAB) (OTC: INNPF) Completes the Purchase of Assets Including Established Extraction & Production Facility in Washington State

VANCOUVER, British Columbia , May 30, 2019 (GLOBE NEWSWIRE) — Nabis Holdings Inc. formerly Innovative Properties (CSE:NAB) (OTC: INNPF) (FRA: 71P) (“Nabis” or the “Company”), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, today announced that it has completed the previously announced purchase of certain assets from PDT Technologies LLC (“PDT”), including extraction and production equipment and rights to lease its current production facility in Port Townsend, WA. The purchase includes the exclusive licensing rights to Chong’s Choice brand products throughout the state of Washington.


A Bullish Case For US Marijuana Stocks: One Stands Out

Over the past few years, the number of companies operating in this market has grown by leaps and bounds. Producers are focused on expanding their customer base by offering a wide portfolio of products and through geographical expansion.


AgraFlora Organics International Inc. (PUFXF) Applies for Industrial Hemp License to Pursue Proprietary CBD Cultivar Development

AgraFlora Organics International Inc. (“AgraFlora” or the “Company“) (CSE: AGRA) (PU31.F) (OTCPK: PUFXF), a growth oriented and diversified international cannabis company, is pleased to announce the Company has applied for licensing with Health Canada under the Industrial Hemp Regulations of the Cannabis Act. The Company anticipates that license approval could be granted in the third quarter of 2019, which will subsequently equip AgraFlora with the ability to seed, cultivate and harvest industrial hemp at its flagship 2.2 million square foot Delta, BC facility.


Disclaimer: Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Innovative Properties Inc dba Nabis Holdings, Midam has been paid $500,000 from Innovative Properties Inc dba Nabis Holdings for a period from 4/10/2019 to 7/25/2019. Midam has been compensated an additional $400,000 and 200,000 common restricted shares of Nabis Holdings to extend coverage an additional 6 months ending 1/25/2020. We may buy or sell additional shares of Innovative Properties Inc dba Nabis Holdings in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Innovative Properties Inc dba Nabis Holdings.

Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Agraflora Organics International Inc. (CSE: AGRA) (OTC: PUFXF), Midam is being paid $25,000 per month by Agraflora Organics International Inc. (CSE: AGRA) (OTC: PUFXF) for 6 months during a period of coverage from May 6, 2019 to November 6, 2019. We may buy or sell additional shares of (CSE: AGRA) (OTC: PUFXF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Agraflora Organics International Inc. (CSE: AGRA) (OTC: PUFXF). Click Here For Full Disclaimer.

Published at Thu, 30 May 2019 12:40:37 +0000

CB2 Insights Posts Strong Growth in Clinical Revenue and Drives Operating Efficiencies in Q1 2019

CB2 Insights Posts Strong Growth in Clinical Revenue and Drives Operating Efficiencies in Q1 2019

CB2 Insights (CSE:CBII; OTCQB:CBIIF) (“CB2” or the “Company”), a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real World Evidence (“RWE”), today reported its results for the first quarter of 2019. Additional information concerning the Company, including its unaudited financial statements and related management’s discussion and analysis (“MD&A”) for the quarter ended March 31, 2019, can be found at www.sedar.com and on the Company’s website. All amounts are expressed in Canadian dollars unless otherwise noted.

Q12019 Financial Highlights

  • Revenue for the quarter was $2.9 million, a 16.4% increase over the previous quarter and based solely on organic growth within the Company’s Canna Care Docs brand;
  • Revenue contribution from its newly acquired MedEval and Relaxed Clarity clinic groups would have been an estimated $500 thousand for the quarter, which would have boosted revenue to $3.4 million for the quarter and increased the Company’s revenue growth rate to over 37% quarter-over-quarter;
  • Gross profit of $2.2 million for the quarter, or gross margin of 77% represents an increase from 70% from the prior quarter;
  • Operating expenses for the quarter were reduced by more than $785 thousand from the prior quarter as a result of management’s operational efficiency analysis;
  • At quarter end the Company had cash of $1.6 million on hand compared to $433 thousand from the prior quarter; and
  • Adjusted EBITDA1 loss of $713 thousand in Q1 2019 versus Adjusted EBITDA loss of $1.81 million in Q4 2018*.

*Note: Q1 2019 Adjusted EBITDA1 from US clinical operations (not inclusive of any subsequent-to-quarter-end acquisitions) resulted in a gain of $578 thousand. CB2 currently uses this surplus in cash flow to fuel its Data and Analytics business, which includes but is not limited to software development, product development, analytical and commercialization teams.

“CB2 saw a strong organic growth in our top line paired with a substantial reduction in our operating expenses in the quarter. This growth did not include contributions from our new, profitable clinical acquisitions of MedEval and Relaxed Clarity,” said Prad Sekar, CEO, CB2 Insights. “We remain committed to growing our clinical business, reducing our burn rate and working towards commercializing our RWE / data asset. We have made significant progress in each of these areas over the past quarter and are confident that our valuation should begin to reflect this. Over the past several months, we have had meaningful conversations with many large-scale traditional Life Sciences stakeholders and are working towards commercialization of our data assets to help usher in a new level of understanding regarding cannabinoid therapy across the traditional healthcare sector. As we look to continue acquiring additional clinical groups in the coming quarters, we are excited to have received validation by major industry players that the path that we are on holds significant prospective value to those both inside and even more so, outside the medical cannabis industry.”

Q1 2019 Operational and Strategic Highlights

Operational and Strategic Highlights Subsequent to Quarter End

CB2 Insights’ Divisional Highlights

CB2 Insights operates 3 primary divisions in the generation of health outcome data. These divisions are:

Clinical Operations: CB2 currently operates the largest network of physician-staffed medical centers in the US specializing in qualifying and supporting patients who are treating their indications with medical cannabis.

  • Added 4 new clinic locations within the quarter under Canna Care Docs brand;
  • Subsequent to quarter-end, successfully acquired Colorado-based Relaxed Clarity; and
  • Subsequent to year-end, successfully acquired Colorado and Arizona-based MedEval Clinics LLC.

Technology: CB2 has developed and deployed its proprietary cannabis-specific Electronic Health Record (EHR) technology platform to standardize the patient and clinical workflows within its clinics ensuring valid and structured anonymized and aggregate data collection protocols to support Real-World Data collection.

  • Successful integration of proprietary Sail EHR platform into Relaxed Clarity and MedEval Clinics LLC; and
  • Began integration with large EMR platform, Premier Health Group to provide access of CDS tool to nearly 5,000 physicians.

Data Insights: Applies analytical, machine learning and artificial intelligence (AI) technologies to the data the Company generates to derive insights that support stakeholders within the Life Sciences industry including drug manufacturers, patients, doctors/HCPs, regulators and payors.

  • Artificial Intelligence expert, Dr. Randy Goebel joins CB2 Insights as Sr. Advisor to Data Insights Division; and
  • Company engaged in successful exploratory sessions with international regulatory bodies, pharmaceutical companies and insurance firms to discuss Real World Evidence support for issues related to cannabis-based drug development, regulatory frameworks and drug spend.
    Quarter ended March 31, 2019   Quarter ended December 31, 2018
  Revenue   $2,849,811   $2,449,020
  Cost of sales   $655,688   $747,496
  Gross Profit   $2,194,123   $1,701,524
  Gross Margin   76.9%   69.5%
  Adjusted EBITDA1   $(712,582)   $(1,811,463)
  Net Income (Loss)   $(2,161,546)   $(2,539,776)
  Basic and diluted net loss per share   $(0.031)   $(0.0452)

CB2 is also announcing that it has completed a rights offering which was previously announced on February 27, 2019. Under the terms of the rights offering, CB2 issued a total of 7,281 common shares at a price of $0.45 per share for aggregate gross proceeds of $3,276.45.

The rights were issued to holders of record on February 15, 2019, prior to the completion of the Company’s reverse take over transaction with MVC Technologies Inc. No stand-by commitment or additional subscription privilege had been agreed and no commission was payable in connection with the rights offering. All unexercised rights are now null and void.

Following the completion of the rights offering, CB2 will have a total of 78,778,036 common shares issued and outstanding.

The net proceeds of the offering will be used for general working capital.

Earnings Conference Call

CB2 Insights’ management team will hold a conference call to discuss our 2019 Q1 Earnings on May 31, 2019 at 9:00am EDT (details below).

  Date:   Friday, May 31, 2019
  Time:   9:00 a.m. (EDT)
  US/Canada Toll Free Dial In:   1-800-319-4610
  Toronto Local Dial In:   1-416-915-3239
  International Dial In:   1-604-638-5340
  Call Name:   CB2 Insights Earnings Call

An archived replay of the conference call will be available on the Company’s website within 24 hours following the conclusion of the call.

Non-GAAP Financial Measures

This Press Release contains references to Adjusted EBITDA and Gross Margin. These financial measures are not measures that have any standardized meaning prescribed by IFRS and are therefore referred to as non-GAAP measures. The non-GAAP measures used by the corporation may not be comparable to similar measures used by other companies. Adjusted EBITDA is defined as “income (loss) before interest expenses, taxes, expenses related to listing on the Canadian Securities Exchange, depreciation, foreign exchange and financial expenses.

The Company uses these non-GAAP measures because they provide additional information on the performance of its commercial operations. Such tools are frequently used in the business world to analyze and compare the performance of businesses; however, the Company’s definition of these metrics may differ from those of other businesses. CB2 Insights will, at times, use certain non-GAAP financial measures to provide readers with additional information in order to assist investors in understanding our financial and operating performance. CB2 Insights believes that these non-GAAP measures provide readers with useful information about the Company’s operating results, enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

Adjusted EBITDA excludes the effect of share-based compensation expenses and related payroll taxes as well as removes substantial one-time costs for unusual business activities. Within the 2018 reporting period, one-time costs associated with fees pertaining to the Company’s public listing are excluded from this figure. Additional discussion on this can be found in CB2 Insights’ Management Discussion and Analysis filed on SEDAR.

Such non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, the corresponding measures calculated in accordance with IFRS. See the Company’s audited Financial Statements for a reconciliation of the non-GAAP measures.

About CB2 Insights

CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry.

For more information please visit www.cb2insights.com.

Primary Contact:
Dan Thompson
Chief Marketing Officer
1.416.670.9316
dan.thompson@cb2insights.com

For Investor Inquiries:
Sean Peasgood
+1.647.362.8286
investors@cb2insights.com

For Media Inquiries:
KCSA Strategic Communications
cb2@kcsa.com

Forward-Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the opportunity to provide services and software to the U.S. cannabis industry.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein. 

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

Primary Logo

Published at Thu, 30 May 2019 20:22:01 +0000

Chemesis International Inc. Reports Fiscal Q3 2019 Financial Statements

Chemesis International Inc. Reports Fiscal Q3 2019 Financial Statements

Chemesis International Inc. (CSE: CSI) (OTC: CADMF), announces unaudited fiscal Q3 Financial Statements for the three months ending March 31, 2019. In this quarter;

  • the Company reported Revenue of $3,762,139, a 33% increase over the previous quarter, with Gross Profit of $1,113,903.
  • the Company closed the acquisition of La Finca Interacviva-Arachna Inc. SAS, an integrated cannabis company operating in Colombia with access to over 1,060 acres of outdoor cultivation.
  • the Company entered into a definitive agreement to manufacture a Proprietary Patent Pending THC Flake.
  • the Company announced an exclusive partnership with First Medical Cannabis bringing immediate access to 1,000 acres of hemp cultivation in Puerto Rico. Additionally, the Company has the option to expand to an additional 5,000 acres.

SUBSEQUENT EVENTS

  • the Company announced the closing of CDN $1,975,000 in equity financings.
  • the Company completed a definitive agreement for Acquisition of an extraction & manufacturing facility in Cathedral City. The acquisition expanded the Company’s processing ability to over 500,000 kg of cannabis annually.
  • the Company announced multi-state expansion into the Central United States, with teams concentrating on establishing operations in Michigan, Wisconsin, Missouri, and Illinois.
  • the Company announced it has received approval for three new cultivation licenses in Colombia, with the ability to expand to over 100 acres. Additionally, through its non-profit organization, Chemesis believes it will extend its sowing prospects to add an additional 10,000 acres within the next three years.
  • the Company announced it agreed with the holders of a $5.5 million promissory notes issued in connection with the Company’s acquisition of La Finca Interacviva-Arachna Med SAS to settle the full amount by issuing 4,104,476 common shares subject to 24 month leak out and escrow agreement.

Edgar Montero, CEO of Chemesis stated, “the Company’s operations continue to see increases in revenue quarter over quarter and we anticipate our operations will continue to grow as we see significant demand for the products we manufacture and package. The company’s revenues, accounts receivables, and inventory is as strong as ever. Chemesis is also putting forth further resources to expand into the Eastern United States to continue to expand the Company’s multi-state operations. The team has created a foundation that we believe will create significant opportunities in 2019.”

Chemesis international still has access to $32,625,000 in drawdown equity facilities between New York based Alumina Partners Inc and Global Emerging Markets at the company’s discretion.

The unaudited condensed consolidated interim financial Statements and MD&A for the three months ended March 31, 2019 will be filed on SEDAR and available at www.sedar.com.

On Behalf of The Board of Directors
Edgar Montero
CEO and Director

About Chemesis International Inc.

Chemesis International Inc. is a vertically integrated U.S. Multi-State operator with International operations in Puerto Rico, and Colombia.

The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it enters new markets and is committed to differentiate itself by deploying resources in markets with major opportunities. The Company operates a portfolio of brands which cater to a wide community of cannabis consumers, with focus on quality and consistency.

Chemesis has facilities in both Puerto Rico and California, and is in the process of constructing a GMP certified facility in Colombia. Chemesis’ Puerto Rico operations are licensed to operate 100,000 ft2 of cultivation, and 35,000 ft2 of manufacturing floor space. The Company is positioned to win additional licenses in highly competitive merit-based US states, and will expand its footprint to ensure it maintains a first mover advantage.

Investor Relations:
ir@chemesis.com
1 (604) 398-3378

Social Media:

Chemesis.facebook
Chemesis.twitter
Chemesis.instagram
DesertZen.instagram
CaliforniaSap.instagram
Jay&SB.instagram

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business, its product offerings and plans for sales and marketing, including finalizing an acquisition in Colombia. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

Primary Logo

Published at Fri, 31 May 2019 00:37:07 +0000

mCig, Inc. (MCIG) Announces Strategic Agreement With Amare Technologies, Inc.

mCig, Inc. (MCIG) Announces Strategic Agreement With Amare Technologies, Inc.

mCig, Inc. (MCIG) a leading distributor of innovative products, customized packaging solutions, technologies, and services for the global medical cannabis industry, is pleased to announce that it signed a strategic agreement with Amare Technologies Inc., a lighting company (https://www.amarelights.com/).  MCIG, through its wholly own subsidiary, CBJ Distributing Inc., that distributes the line of cannabis supply items, such as: labels, jars, child proof envelopes, vape pens, to almost all dispensaries in Nevada, while enlarging its market share in southern and central California, will be stocking Amare’s commercial LED fixtures with in-store displays that exhibit Amare’s smart LED technology controlled by their smartPAR™ cloud-based software. Additionally, CBJ knowledgeable sales professionals will be providing local sales support for the cannabis market in these regions.

Paul Rosenberg, CEO of mCig Inc., said, “Our partnership with Amare Technologies demonstrates our commitment to offering the latest high-tech products to its customers. Until now, there haven’t been options for growers to access and demo adjustable LED hardware and software from their local retail store. We’re happy to give Amare Technologies access to our powerful distribution network, and to be a strategic partner to sell and market their products.”

Amare has been helping growers get the most out of their resources and time since 2014 with high performance, value-added LED horticulture lighting solutions.  “Today, we are introducing the SolarBar800(Bar8), our most efficient and powerful horticulture lighting solution to date,” stated Victor Nguyen, CEO of Amare Technologies Inc. and COO of mCig Inc.,  designed specifically for commercial cannabis cultivation requiring high ppfd and productivity.

Featuring up to 2.9J electrical efficiency and 900w, the Bar8 is exceptionally efficient and powerful, yet flexible with a recommended mounting height over canopy of 6-60″(6-18″ without lenses, 24-60″ w/optional lenses) to accommodate single and multi-tier applications.  Innovation and precision have always been part of our design philosophy and the Bar8 is no exception.  The results are detachable bars that can used in pairs for additional coverage, side/supplemental lighting, etc. and remote power supply.

Please visit, https://www.amarelights.com/ for more information about our new products.

About MCIG Group (MCIG)

Headquartered in Jacksonville, Florida, mCig, Inc. (MCIG) is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. mCig, Inc. is committed to be the leading distributor of technology, products, and services to fit the needs of a rapidly expanding industry. mCig, Inc. employs a world-renowned tech team and has recently expanded its products and services to satisfy its evolving role in cannabis and hemp markets.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.

Contact: mCig, Inc.

Paul Rosenberg

paul@mciggroup.org

Published at Wed, 29 May 2019 12:48:45 +0000

Vapen Is Well Positioned To Capitalize On The Arizona Medical Market

Vapen Is Well Positioned To Capitalize On The Arizona Medical Market

Earlier this month, we highlighted VapenMJ (VAPN.CN) ahead of its go-public transaction and we hope you have been watching this emerging opportunity.

Following the completion of a successful go-public transaction, Vapen has been trending higher and this is an opportunity to be watching. During the last year, we have seen a significant increase in the amount of interest in United States focused cannabis businesses and this is an area that Vapen has been laser focused on.

Initially, Vapen has been capitalizing on the medical cannabis market in Arizona and has been targeting new markets as part of its expansion. One of the reasons we are excited about this cannabis company is due to the focus on the cannabis concentrate market and we find this to be significant.

Vapen is a leading medical cannabis concentrate brand in Arizona and has distribution of the 100+ dispensaries in the state. Last month, Select, a leading cannabis concentrate brand, was acquired for approx. $1 billion (CAD) and believe that this bodes well for a company like Vapen. Over the next year, we expect the cannabis concentrate market to record massive growth and this market is just getting started. According to BDS Analytics, the cannabis concentrate market is expected to be generating approx. $8 billion in retail sales by 2022 and this represents a massive opportunity for companies like Vapen.

We have been bullish on the cannabis concentrate market and believe this is an area where investors need to be focused on. According to BDS Analytics, cannabis concentrates represent approx. 26.6% of the entire United States market and has been gaining market share at a rate that is faster than any other cannabis product type. Vapen is well positioned to capitalize on the increasing demand for cannabis concentrates and we will be monitoring how the team executes from here.

Focused on Expanding into California and Nevada

Arizona is the third largest medical cannabis market in the United States and we expect the recreational cannabis market to open after the 2020 election. We are bullish on the opportunity in Arizona and are favorable on Vapen’s ability to execute and gain significant market share in this market. If recreational cannabis legislation is approved in Arizona, this will prove to be a major catalyst for the cannabis concentrate brand and would benefit companies like Vapen.

One of the reasons we are excited about Vapen is due to its plans to expand into markets that already has a recreational cannabis market and we are favorable on the growth prospects associated with this.  When looking at the markets that the company is targeting for an expansion, we are most excited about the opportunity in California and Nevada. In these markets, the demand for cannabis concentrates has been significant and we are bullish on this opportunity for Vapen.

Over the next year, we expect the entrance into new markets to be the most significant value driver for Vapen. The opportunity in Arizona is very important and we expect a change in regulations to be a major catalyst for the business. We believe that Vapen is focused on selling the right products in the right markets and are bullish on the growth prospects going forward.

An Emerging Growth Opportunity

One of the reasons we are confident in Vapen’s ability to expand is due to the management team that is place. We believe that the company is led by an executive team that has a proven track record of success and this is an important aspect of the business. We are favorable on the management team’s ability to create value for shareholders as well as the cannabis markets that it is focused on.

Vapen has several major potential catalysts for growth and is led by a management team that is laser focused on execution. The company offers a premium product line and has done an incredible job when it comes to executing on the Arizona medical cannabis market. Going forward, we expect to see Vapen enter new markets and expect revenue numbers to ramp higher as the team continues to execute.

Although the recent rally has been significant, the valuation is attractive when compared to its peers and we believe that this is an opportunity to be watching. Vapen is in the middle of a major growth cycle and we are favorable on the risk-reward profile.

The cannabis concentrate market represents a multi-billion-dollar market and we are favorable on the opportunity that Vapen has to capitalize on it. To learn more about the cannabis concentrate company, please email support@technical420.com.

Pursuant to an agreement between StoneBridge Partners LLC and Vapen MJ Ventures we have been hired for a period of 180 days beginning May 13, 2019 and ending November 13, 2019 to publicly disseminate information about (VAPN) including on the Website and other media including Facebook and Twitter. We are being paid $6,500 per month (VAPN) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero (0) shares of (VAPN), which we purchased in the open market. We plan to sell the “ZERO” shares of (VAPN) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (VAPN) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share

Share - Facebook


Share - Twitter

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Wed, 29 May 2019 11:07:52 +0000

mCig, Inc. (MCIG) Announces Strategic Agreement With Amare Technologies, Inc.

mCig, Inc. (MCIG) Announces Strategic Agreement With Amare Technologies, Inc.

mCig, Inc. (MCIG) a leading distributor of innovative products, customized packaging solutions, technologies, and services for the global medical cannabis industry, is pleased to announce that it signed a strategic agreement with Amare Technologies Inc., a lighting company (https://www.amarelights.com/).  MCIG, through its wholly own subsidiary, CBJ Distributing Inc., that distributes the line of cannabis supply items, such as: labels, jars, child proof envelopes, vape pens, to almost all dispensaries in Nevada, while enlarging its market share in southern and central California, will be stocking Amare’s commercial LED fixtures with in-store displays that exhibit Amare’s smart LED technology controlled by their smartPAR™ cloud-based software. Additionally, CBJ knowledgeable sales professionals will be providing local sales support for the cannabis market in these regions.

Paul Rosenberg, CEO of mCig Inc., said, “Our partnership with Amare Technologies demonstrates our commitment to offering the latest high-tech products to its customers. Until now, there haven’t been options for growers to access and demo adjustable LED hardware and software from their local retail store. We’re happy to give Amare Technologies access to our powerful distribution network, and to be a strategic partner to sell and market their products.”

Amare has been helping growers get the most out of their resources and time since 2014 with high performance, value-added LED horticulture lighting solutions.  “Today, we are introducing the SolarBar800(Bar8), our most efficient and powerful horticulture lighting solution to date,” stated Victor Nguyen, CEO of Amare Technologies Inc. and COO of mCig Inc.,  designed specifically for commercial cannabis cultivation requiring high ppfd and productivity.

Featuring up to 2.9J electrical efficiency and 900w, the Bar8 is exceptionally efficient and powerful, yet flexible with a recommended mounting height over canopy of 6-60″(6-18″ without lenses, 24-60″ w/optional lenses) to accommodate single and multi-tier applications.  Innovation and precision have always been part of our design philosophy and the Bar8 is no exception.  The results are detachable bars that can used in pairs for additional coverage, side/supplemental lighting, etc. and remote power supply.

Please visit, https://www.amarelights.com/ for more information about our new products.

About MCIG Group (MCIG)

Headquartered in Jacksonville, Florida, mCig, Inc. (MCIG) is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. mCig, Inc. is committed to be the leading distributor of technology, products, and services to fit the needs of a rapidly expanding industry. mCig, Inc. employs a world-renowned tech team and has recently expanded its products and services to satisfy its evolving role in cannabis and hemp markets.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.

Contact: mCig, Inc.

Paul Rosenberg

paul@mciggroup.org

Published at Wed, 29 May 2019 12:48:45 +0000

WeedMD to Convert Aylmer Facility to Cannabis Extraction and Processing Hub

WeedMD to Convert Aylmer Facility to Cannabis Extraction and Processing Hub

WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that it is converting its fully-licensed 26,000 sq. ft. Aylmer, Ontario facility to a large-scale cannabis extraction and processing operation.

“WeedMD is optimizing its two licensed facilities to allow each to focus on a core vertical and to streamline our operations. We are transitioning the Aylmer site to produce a wide range of extracts and concentrates,” said Keith Merker, CEO of WeedMD. “All cultivation has been consolidated to our greenhouse and outdoor Strathroy facility, which is delivering consistently improving yields at increasingly competitive costs.”

About the Aylmer Extraction Facility

WeedMD is retrofitting its Aylmer operation into a purpose-built cannabis oil extraction facility that will be operational by summer 2019. Additional details:

  • WeedMD is building on its experience in extract production, having processed oils onsite at Aylmer since June 2017
  • The site is fully licensed for cannabis oil production and sale
  • The Company will have four extraction lines in operation with the ability to process over 200,000 kgs of biomass annually
  • WeedMD will utilize various extraction methods in order to meet the demands of the market
  • The Company will provide formulation capabilities for wholesale and white label manufacturing
  • The facility is being built to GxP* standards to support compliance for both domestic and international markets
  • The existing fully-licensed 26,000 sq. ft. facility is located on an expandable four-acre site wholly-owned by WeedMD
  • WeedMD will supply a large quantity of input material for cannabis extraction from the greenhouse and outdoor production from its Strathroy site

*GxP encompasses a broad range of compliance-related activities such as Good Laboratory Practices, Good Clinical Practices and Good Manufacturing Practices.

As recently announced, WeedMD’s Strathroy cultivation facility is expected to yield more than 150,000 kgs of dried flower per year in 2020.  Outdoor grow video here.

For more information, access WeedMD’s investor presentation here and recently updated corporate video here.

About WeedMD Inc.
WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of cannabis products for both the medical and adult-use markets. The Company owns and operates two facilities: a 26,000 sq. ft. indoor facility in Aylmer, Ontario and a 158-acre state-of-the-art greenhouse and outdoor facility located in Strathroy, Ontario. The Company currently has 136,000 square feet of licensed production space across its facilities and is expected to have a total footprint of more than 550,000 square feet of indoor and greenhouse production in addition to more than 25 acres of outdoor cultivation space online in the first half of 2019. WeedMD has a multi-channeled distribution strategy that includes selling directly to medical patients, strategic relationships across the seniors’ market and supply agreements with Shoppers Drug Mart as well as six provincial distribution agencies.

Follow WeedMD On:

Facebook: https://www.facebook.com/weedmd/
LinkedIn: https://www.linkedin.com/company/weedmd/?originalSubdomain=fr
Twitter: https://twitter.com/WeedMD
Instagram: https://www.instagram.com/weedmd/

For further information, please contact:

WeedMD Inc.

Keith Merker, Chief Executive Officer
Tel: 519-765-2440 Ext. 201
Email: investor@weedmd.com

To learn more, visit us at www.weedmd.com

For Media Inquiries:

Marianella delaBarrera
VP, Communications & Corporate Affairs
Tel: 416-897-6644
Email: marianella@weedmd.com

Cautionary Statement on Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation which are based upon WeedMD’s current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy.

The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information in this news release include, but are not limited to, statements with respect to internal expectations, expectations with respect to actual production volumes, expectations for future growing capacity and the completion of any capital project or expansions. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally; the ability of WeedMD to implement its business strategies; competition; crop failure; and other risks.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, WeedMD does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for WeedMD to predict all such factors. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in WeedMD’s Annual Information Form dated December 13, 2017 (the “AIF”) and other disclosure documents of WeedMD filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the AIF and other disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information.

______________________________________________________________________________________________
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

Primary Logo

Published at Wed, 29 May 2019 11:18:16 +0000

Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) Offers Ultra Pure CBD Oil To The Consumers In British Columbia

Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) Offers Ultra Pure CBD Oil To The Consumers In British Columbia

Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) has launched ultra pure sync 25 CBD oil to fill the recreational space in British Columbia. It is a smoke-free and non-THC alternative to the consumers.

Emerald has sent 6,000 40 ml units of Sync 25 CBD oil to BCLDB (British Columbia Liquor Distribution Branch). Executive Chairman and President of Emerald, Dr. Avtar Dhillon said the company is pleased to introduce wellness product SYNC 25 under its brand to fill the gap in the recreational market of British Columbia.

Extraction of SYNC 25 CBD oil

The new product launch is part of Emerald’s growth strategy, and to enjoy higher profit margins through developing quality and innovative products. Medipharm Labs Inc extracts the SYNC 25 CBD oil for Emerald.

CEO of Medipharm, Pat McCutcheon said the company’s expertise in extracting the SYNC 25 CBD oil complements the success of Emerald to introduce the product to meet the growing demand. The company will strive to supply high-quality cannabis concentrates on supporting the expansion plans of Emerald. SYNC 25 CBD oil is available online for immediate purchase.

Appointment of Chief Operating Officer

Emerald has posted Sean Rathbone as COO. He will contribute expertise in technology advancement, corporate process management, operational leadership, raw materials refinement, and waste reduction.

Executive Chairman said Rathbone is an industrial engineer and brings experience in promoting the growth of operational mandate on a large scale. Rathbone will play a vital role in introducing technologies, processes, and policies to achieve the production targets as Emerald continues on an expansion spree to satisfy the growing demand for cannabis products in Canada. He will ensure operational efficiencies and maintain performance standards companywide.

Rathbone has played the role of Vice President (Production), Western Canada at Agropur. He also worked as a Manager (Manufacturing R&D) BDO Canada LLP.

Standard processing license

Health Canada has awarded standard processing license to Pure Sunfarms for 1.1 million sq. Ft Delta 3 Greenhouse facility. The license allows Pure Sunfarms the extraction and processing of cannabis at Delta 3 Greenhouse facility. Emerald holds a stake of 50% in the joint venture: Pure Sunfarms, which requires an amended sales license to market cannabis oil.

Published at Wed, 29 May 2019 12:01:33 +0000